Life Sciences Archive » November, 2015

Life Sciences - November, 2015

294 articles

• Blank Rome DQed From Boston Scientific Kickback Suit
• Dow Can't Dodge $456M Award In Patent Row, Bayer Says
• Thermo Fisher Wins Sanctions Bid In PE Group's Fraud Suit
• Amgen Seeks 1st Biosimilar Of Mega-Blockbuster Humira
• Fla. Pharmacy Recalls Vitamins For 'Severe' Vitamin D Risks
• Teva Launches $6.75B Offering To Back Allergan, Rimsa Deals
• Allergan, NY End Antitrust Fight Over Dementia Drug
• Montel-Endorsed Apparel Co. Scammed Consumers, FTC Says
• Sheppard Mullin Snags Snell & Wilmer Deal-Maker In LA
• Actavis Says Travelers Owes Defense In Opioid Abuse Suits
• Kirkland Steers Teva In Japanese Generics Venture
• Justices Reject Biolitec's $70M Contempt Appeal
• IRS Calls Mylan Patent Deal A 'License' In $100M Tax Fight
• High Court Won't Hear $176M Covidien Prior Art Appeal
• Life Sciences MVP: Sterne Kessler's Eldora Ellison
• A New Paradigm For Prescription Drug Labeling?
• MedTel Found In Contempt Again In Heart Monitor IP Fight
• Pozen Fires Back At Bass Group's Vimovo IPR Petition
• P&G Says Fixodent Users' Appeal Is Backed By Bad Evidence
• Teikoku Loses Bid To Boot 12 Firms From Lidoderm MDL
• Bio-Rad Will Ask 9th Circ. To Nix Whistleblower GC's Claims
• Medicines Co. Asks Fed. Circ. To Reopen IP Fight With Mylan
• Wright Hit With $11M Jury Verdict In Hip Implant Bellwether
• Herbalife KOs Pyramid Scheme Suit In Latest Round
• WuXi PharmaTech Shareholders OK $3.3B Go-Private Deal
• Kimberly-Clark Says Rival Recycling Arguments In Diaper Spat
• Dr. Reddy's Denied Stay In AstraZeneca Purple Pill Row
• Bass Takes Aim At Citius Drug Patent Under His Own Name
• WTO Dispute Roundup: Members Clash Over Ag, E-Payments
• Ore. Gets Suit Over J&J's Motrin 'Phantom Recall' Revived
• OPINION: In Search Of Our Best Law Firm Selves
• Convicted Ex-BNY Employee Settles SEC Insider Trading Case
• AstraZeneca's Cancer Drug Suit In Wrong Venue, Mylan Says
• An In-House Cheat Sheet On Tax Inversion Deals
• Deals Rumor Mill: Bain Capital, Syngenta, Deutsche Wohnen
• Life Sciences MVP: Paul Weiss' Nicholas Groombridge
• A Closer Look At Fed. Circ.'s Ruling In ClearCorrect
• Chicago Improves Opioid Case With Details About Doctors
• Life Sciences MVP: Latham & Watkins' Charles Ruck
• NJ High Court To Review Reversal Of $25M Accutane Verdict
• Shire Blocks Par From Selling Adderall Generic
• GOP Sens. Back Generic-Drug Imports As Prices Soar
• FDA Warning Wire: Suspect Records At Sandoz, Dr. Reddy's
• The 3 Biggest Myths About Tax Inversion Deals
• Consumers Say Claims Against Homeopathics Are Supported
• Bayer Can't Duck All Claims In Mirena IUD Lawsuit
• Eli Lilly Can't Escape Darvocet Suits While JPML Mulls Remand
• Dechert Nabs Energy, Pharma Deals Pro In London
• New Federal Rules Acknowledge It's Time To Drop The 'E'
• Bayer Urges Fed. Circ. To Nix $6M Award To Dow In IP Row
• Health, Life Sciences Cos. Have Most IP Theft Issues: Report
• 2015: A Blockbuster Year In Health, Life Sciences M&A
• Patients Urge 1st Circ. To Revive Sanofi Drug Dispute
• Antitrust Concerns Won't Derail $160B Pfizer-Allergan Deal
• The 7 Firms Behind The Mammoth Pfizer-Allergan Merger
• Botox Buyer Rips Allergan's Bid To Slip Price-Fixing Suit
• Cymbalta Users Appeal To 9th Circ. In Withdrawal Suit
• Record Inversion Deal Shows Pfizer Unfazed By New Rules
• Sanofi Says K&L Gates, Rival Stalling Sanctions In FCA Suit
• Pharma Cos. Say Chicago's Opioid Suit Lacks Specifics
• IP Firm Merchant & Gould Adds Life Sciences Pro In DC
• Life Sciences MVP: Kirkland & Ellis' Jay Lefkowitz
• Medical Device Maker Gets $7.5M From Jury In Contract Suit
• Prestige Inks $225M Deal With PE Firm For DenTek Oral Care
• Class Counsel Fees Getting 'Intense Judicial Scrutiny'
• Pfizer, Allergan To Merge In $160B Deal
• Eli Lilly Brazil Unit Not Covered In Tort Suits, Insurer Says
• Mylan, Perrigo Settle Suit After $27B Hostile Takeover Row
• Accident Victim Looks To Keep Pain Meds Out Of GM MDL Trial
• Heller Ehrman Slips $100M IP Malpractice Suit In 9th Circ.
• Albertsons Sold Unapproved ADHD Generic Drug, Parent Says
• GSK Loses Bid To Nix Experts Of Reed Smith Atty's Widow
• Novartis Faces Strict Pharmacy Oversight In $390M Deal
• Shareholder Suit Another Bitter Pill For GNC After Ore. Action
• New IRS Crackdown Not Enough To Halt Inversion Deals
• Deals Rumor Mill: Pfizer, 1MDB, Diebold
• Cancer-Drug Maker's FDA Data Incited Stock Drop, Suits Say
• Life Sciences MVP: Kirkland & Ellis' Jim Hurst
• Mylan, Ranbaxy Urge Stay Of Provigil Pay-For-Delay Suits
• Horizon Withdraws Depomed Bid After Blow In Calif. Court
• 3 Ways Technology Is Changing Law Office Designs
• Mirowski Blasts $6M Atty Fee Bill In Medtronic Patent Suit
• Hi-Tech Fails To DQ FTC's Trial Team In Labeling Row
• Ex-Stryker Salesman Can't Duck Employee Poaching Claims
• 13 Key Business Objectives For Corporate Legal Departments
• Life Sciences MVP: Irell's David Gindler
• Deals Rumor Mill: Pfizer, Cosco Group, Towers Watson
• IRS Announces Fresh Crackdown On Inversion Deals
• Pacira Escapes Shareholder Suit Over Drug Marketing
• J&J, Conn. Woman Spar Over 'Natural' Baby Wash Labels
• Judge Greenlights False Ad Suit Over Gingko Biloba
• Dr. Reddy's Sues To Use Purple Pill For Heartburn Generic
• FTC Gives Final OK To Endo's $8B Par Pharmaceutical Buy
• Charges Against Supplement Execs Can Boost Plaintiffs Attys
• Wright Parent Slips Metal Hip Bellwether As Case Goes To Jury
• NJ Patent Trial Witnesses Recount Drug-Making Challenges
• Fed. Circ. Won't Review PTAB's Decision In Bosch IP Case
• Pa. Risperdal Trial Paused Over Data Analysis Dispute
• Wis. Tribe Sues Feds Over Destroyed Hemp Crop
• Sandoz Submits Third Biosimilar Application To FDA
• Drugmakers Can't Appeal Remand of Darvocet Suits: 6th Circ.
• Bass AIA Challenge To Celgene Cancer Drug Patent Rejected
• Labaton Sucharow To Co-Head Biogen Investor Suit
• Full Fed. Circ. May Blunt On-Sale Bar's Risk To Small Cos.
• Dyax Investor Slams Shire's $5.9B Offer As Too Low
• NY Doc Gets Almost 4 Years In $100M Test-Referral Scheme
• OSI, Pfizer Say Breckenridge Infringed Cancer Drug Patents
• FTC, Profs Urge 3rd Circ. To Revive Pay-For-Delay Complaint
• BALCA Overturns Cert. Denial For Nuclear Medicine Job
• Allergan Slams Fed Preemption Claim In IPR Extortion Row
• Life Sciences MVP: Fish & Richardson's Jonathan Singer
• Federal, Calif. 'Slack-Fill' Laws Ensure Fill Of Litigation
• HIPAA Lessons From The Warner Chilcott Settlement
• FDA Warning Wire: Hangover Drinks, Compound Drugs, Fish
• Orthofix Wins 6th Circ. Appeal In Trade Secrets Row
• Houston Firm Loses Appeal Over Fen-Phen Referral Contract
• Feds Crack Down On Fraudulent Dietary Supplements
• Euro Pacific Fights Bid For Arbitration In $6M Contract Row
• CVS Says Precedent Supports Axing Vitamin E Labeling Suit
• FDA To Finalize Controversial Oversight Of Lab Tests In 2016
• Senate Questions Nominee FDA Chief's Pharma Ties
• Testing Strip Cos. Seek To Nix J&J Unit's Infringement Suit
• Buyers Say Supplement Co. Can't Block Pyramid Scheme Cert.
• Chamber Blasts New Bills Targeting Tax Inversions
• Warburg Pincus Backs New Pharma Co. With Hearty M&A Plans
• Suture Express Wants Liability Ruling In $200M Antitrust Suit
• Intuitive Board Fails To Dodge Claims Over Surgical System
• Fed. Circ. Limits Safe Harbor For Post-Approval Conduct
• J&J Dodges Baby Wash False Ad Class Action
• Boehringer, Teva Slam Aggrenox Buyers' Doc Production
• Surgical Co. Can't Nix Investor Suit Over Lens Implants
• Teva's Planned Generic Aloxi Infringes Helsinn IP, Judge Says
• Diabetes Drug MDL Ruling Helps Branded Cos. In Label Fights
• FDA Urged To Block Sales Of OTC Congestion Drug
• Industry Groups Back J&J Bid To Nix $140M Motrin Verdict
• Taylor-Wharton Unsecured Creditors Attack Key Worker Deal
• New Fla. Medical Pot Bill Revamps Distribution System
• Fed. Circ. Faults PTAB's Order Upholding Verinata Patent
• Supreme Court Won't Tackle $29M Suture Patent Award
• Merck Sales Reps Seek OK To Send Sex Bias Suit Notices
• High Court Passes On Biotech Co. Patent Licensing Fight
• Actavis Wants Courtroom Sealed In Anti-Seizure Drug Trial
• Hi-Tech Blasts FTC For Accessing Imprisoned CEO's Email
• Interference Appeals Not Just For Fed. Circ., Justices Told
• Loestrin Pay-For-Delay Suit Lacks Hard Data, 1st Circ. Told
• House Panel Can't Nix SEC Subpoena In Insider Trading Probe
• Caris Says Chancery Wrongly Backed Workers' Stock Claims
• How Recent Pro-Preemption Wave May Lift Brand-Name Drugs
• Husch Blackwell Adds Ex-Brinks Gilson Atty To Chicago Office
• Should In-House Counsel Use US Contract Terms In Europe?
• Privileged Docs In Adderall Pay-For-Delay Suit Still Off-Limits
• J&J Can't Pare Tylenol Liver Damage Bellwether: Pa. Judge
• Full Fed. Circ. To Review On-Sale Bar In Angiomax Patent Suit
• NY Wholesaler Joins Fray With GSK, Teva Conspiracy Suit
• FDA Orders Recall Of 2,800 Endoscope Cleaning Devices
• Texas Tort Reforms Don't Bar Medical Device Claims
• Wyeth Rejects Claim That It Promoted Off-Label Prescribing
• Sanofi-Aventis Says K&L Gates Can Be Sanctioned In FCA Suit
• Fed. Circ. Incentivizes Offshore Generic Drug Testing
• Take Your Marks: An Associate's Guide To Your 1st Big Trial
• Ex-Pharma Exec Says Indictment Too Thin To Prep Defense
• Mylan Loses Monthslong Perrigo Takeover Battle
• Pfizer, Endo Unit Duck MDL Claims Over Testosterone Drugs
• Express Scripts Sues Horizon For $140M, Cuts Pharmacy Ties
• Pfizer Unit Slams Retailers' Skelaxin Pay-For-Delay Claims
• Procter & Gamble, Rite Aid Again Escape Fixodent Mass Tort
• Supplement Co. Claims Rival Uses Unapproved Drugs
• Fed. Circ. Affirms Hospira Win In Generic Cubicin Patent Suit
• Zimmer's Expert Takedown Poses Hurdles For Knee Patients
• J&J Can't Move Pelvic Mesh Cases Out Of Philly
• 3rd Circ. Asked To Revive Effexor Pay-For-Delay Claims
• Revived Genaera Shareholder Suit Gets Nixed Again
• AstraZeneca Prices $6B Bond To Help Fund ZS Pharma Buy
• Invitation To Clarify How Plaintiffs Prove Class Membership
• J&J Unit Settles Proposed Bellwether In Vaginal Mesh MDL
• Ex-BNY Manager Gets 6 Months For Insider Trading
• Pomerantz Named Lead Counsel In $121M ConforMIS IPO Suit
• Merck's $17B Takeover Of Sigma-Aldrich Gets EU's Final OK
• Endo Has No Privilege To Withold SEC Drafts In Drug MDL
• Valeant Can't Dodge Insider Trading Row Over Allergan Bid
• FDA Warning Wire: Dr. Reddy's, DNA4Life, Cholesterol Pills
• ClearCorrect Ruling Keeps ITC From Policing Web Piracy
• GNC Hit With Suit Over Alleged Illegal Ingredients
• Iovate Settles Spiked Protein Accusations For $2.5M
• Fed. Circ. Revives 1 Of 2 Lovenox Patent Suits
• Calif. City Sues Monsanto, Pfizer Unit For PCB Contamination
• Valeant Workers 'Pissed' About Bogus Allegations, CEO Says
• Seeger Weiss Dodges Widow's Suit Over Vioxx Settlement
• Lawmaker Targets Inversions As Pfizer Mulls Allergan Deal
• Gatorade Owner Drops Trademark Suit Over 'Haterade'
• 3 Pressing Challenges For Personalized Medicine
• ITC Can't Block Infringing Digital Files, Fed. Circ. Says
• Sanofi Faces Contract Suit Over $708M In MS Drug Payments
• Merck, Others Beat Warning Claims In Diabetes Drug MDL
• Herbalife Investors Say Third Time's Charm For Pyramid Suit
• Texas Pelvic Mesh Ruling Could Make Plaintiffs Think Twice
• Arthrex Asks High Court To Review Part Of $95M Patent Loss
• Inside Mylan's Pursuit Of Perrigo
• J&J, Covidien Settle Injunction Spat In Patent Row
• Ethicon Says Mesh Patients Abusing Discovery In MDL
• 3 Key Issues To Watch As Pricing Probes Swamp Big Pharma
• HFF Brokers $96.4M Loan For Calif. Biotech Campus Project
• Watchdog Finds Doping On Russian Athletics Team
• Former Top Advisor, Attorney At FDA Joins Covington in DC
• Abbott Wins Injunction On 'Gray Market' Diabetes Test Strips
• Columbia Dismissed From Bard Pelvic Mesh Coverage Suit
• High Court Asked To Review Standing In Prosthetic IP Row
• German Insurer Says Baxter Docs Not Privileged Under Ill. Law
• J&J Hit With $1.75M Verdict In 4th Philly Risperdal Case
• Justices Refuse Bids To Stop Apotex's Benicar Patent Suit
• The Evolution Of Federal Policy On Human Test Subjects
• 8 Ways Trans-Pacific Partnership Affects Patent Rights
• 3rd Quarter Saw A Rise In FCPA Enforcement
• Did Fed. Circ. Doom The New Biosimilar Approval Pathway?
• Law360's Super MVPs In A Class Of Their Own
• 5 Firms Lead The Pack With MVP Wins
• Law360 MVP Awards Go To Legal Aces From 86 Firms
• High Court Urged To Weigh In On Drug 'Product-Hopping'
• Bayer Sued Over Sterilization Device Essure's Side Effects
• AstraZeneca Blocks Dr. Reddy's Purple Heartburn Pills
• Covidien Urges Justices To Tackle 'Secret Prior Art'
• Provigil Judge Says Experts Can Testify On Patent Strength
• FDA Panel Says Certain Antibiotic Warnings Are Inadequate
• WTO Panel Inks 17-Year Drug Patent Waiver For Poor Nations
• Novartis Sues Amneal, Dr. Reddy's Over Dementia Patches
• 113 Seek Mass Tort In Pa. Over Birth Control Packaging
• Goldman Cashes In Valeant Shares Backing CEO's $100M Debt
• AstraZeneca Inks $2.7B Deal For ZS Pharma
• Taxation With Representation: Fenwick, Ropes, Wachtell
• Hagens Berman Defends Bid to Nix Sanctions At 3rd Circ.
• 5th Circ. Will Rehear Stryker Toe Implant Fight
• Jury Clears Zimmer Of Design Defect In 1st Knee Implant Trial
• Texas Court Kills $1.2M Pelvic Mesh Verdict Against J&J
• Sen. Hatch Says Drug IP Provisions May Doom TPP
• Apotex Wants Lupin Docs In Patent Suit Jurisdiction Row
• PhRMA Backs Merck In 3rd Circ. Over Nixed Fosamax Claims
• FDA Cracks Down On The Dietary Supplement Industry
• Chicago Looks To Revive Dismissed Opioid Conspiracy Suit
• Union Funds Ask Del. High Court To Reinstate False Ad Suit
• All You Need To Know About The Trans-Pacific Partnership
• Teikoku Backs Up Bid To DQ 12 Firms In Lidoderm MDL
• TPP Aims To Spread US-Style IP Protections Overseas
• TPP Leaves Leeway On Biologics Exclusivity
• Jury Deliberating In 1st Zimmer Knee Implant Bellwether
• Ethicon Stapler Suit Belongs Outside US, 6th Circ. Told
• States Are Taking Charge Of Antibiotic Use In Animals
• Pa. Court Axes $1.7M Award In Wyeth Water Treatment Row
• Sex Supplement Suit Not Barred By Federal Law, Judge Says
• Hi-Tech Evades Contempt Finding In FTC Suit For Now
• J&J Can't Dodge Costco Antitrust Claims Over Pricing Policy
• 11th Circ. Urged To Keep Diagnostic Co. Owner's $6M Verdict
• AstraZeneca, Teva Unit Finalize $54M Deal In Medicaid Row
• Bayer Owes MDL Attys $9M For GMO Deal, 8th Circ. Told
• DOJ, SEC Probing Alexion Over FCPA Compliance
• High Court Urged To Review $70M Biolitec Contempt Ruling
• AstraZeneca Wields Amarin Win In FDA Exclusivity Fight
• More Wright Hip Implant Evidence Filtered By Ga. Judge
• OPINION: Via Duke, Companies Are Shaping Discovery
• Med Device Biz To Go Private In $812M Citic Deal
• France Launches Criminal Probe Tied To IAAF Doping Claims
• REMS Abuse And Antitrust Injury: Round Peg, Square Hole
• FTC Names Pay-For-Delay Czar To Interim Antitrust Post
• Atty Knocks Supplement Maker's Sanctions Bid In 3rd Circ.
• Citron's Left Can't Halt HK Case Over Evergrande Report
• Mintz Levin Adds Biopharma IP Member In DC
• FDA Warning Wire: Pfizer's Suspicious Pharma Tests
• Jones Day Adds Former Robbins Geller IP Pro In Atlanta
• Enzo, Applera Spar Over Fate Of DNA-Test Patent Verdict
• AstraZeneca Hits Mylan With Patent Suit Over Blood Thinner
• Mylan Must Sell 7 Generic Drugs Ahead Of Perrigo Deal: FTC
• DOJ Taps Ex-Standard Chartered Bribery Cop For New Role
• Ariosa V. Sequenom Signals Trouble Ahead For Life Sciences
• Strategies For Law Firms Leaping Into Latin America
• Inequitable Conduct Behind Regeneron Patent, Judge Finds
• 2nd Circ. Asked To Uphold Pregnancy Test Recall
• Venture Fund Says PwC Failed To Catch $17M Fraud
• Major Cos., IP Groups Call For Clearer USPTO Alice Rules
• BCBS Fights Dismissal Bid In Aggrenox Pay-For-Delay Suit
• Abbott, AbbVie Win Over Jury In Depakote Birth Defect Row
• 3 Key Questions As Biosimilar Naming Fight Rages On
• HHS Inspector General Details 2016 Investigative Plans
• Evidence Trimmed In Wright Hip Implant Bellwether Case
• Hospira Investor Seeks Stock Appraisal Of $17B Pfizer Deal
• 4 Life Science Cos. Set Terms For IPOs Totaling $276M
• Noven Sues To Block Mylan's Generic ADHD Patch
• Dueling Opinions Tee Up Appeal Over Pa. Risperdal Punitives
• Bristol-Myers Pays $2.1B For Heart Failure Drug Co.
• Blue Shield Faces Suit In Calif. Over Hep C Drug Denials
• Ethicon Blocking Witnesses In Pelvic Mesh MDL, Victims Say
• Simpson Thacher Steers Pamplona On $2.7B MedAssets Deal
• Ropes & Gray Steers Shire To $5.9B Deal For Dyax
• Authenticating Art With Bioengineered DNA: The IP Issues
• Using Information Graphics Effectively In The Courtroom
• 5 Takeaways From The Novartis FCA Settlement